Advertisement Pharmaceutical Business review - Page 126 of 5257 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 20, 2026

iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s

iRegene Therapeutics has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead product, NouvNeu001, aimed at treating Parkinson’s disease.

NouvNeu001 is intended for the treatment of Parkinson’s disease. Credit: meeboonstudio / Shutterstock.com.